Phase II Melanoma Trial
Viralytics has had approval from the US FDA through an Investigational New Drug (IND) application, to carry out it's Phase II melanoma trial in the USA.
This Phase II study is entitled the CALM Study (CAVATAK™ in Late stage Melanoma). This is a 54 evaluable patient trial. The dosing schedule provides for injections of CAVATAK™ into multiple tumours over an 18 week treatment phase and monitoring for immune related progression free survival at 6 months. Patients and clinicians seeking further information on this trial can visit our Clinical Trial page.